Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience
E Higashihara, VE Torres, AB Chapman… - Clinical Journal of the …, 2011 - journals.lww.com
Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced
adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls
1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m 2) were similar. Control TKV
increased 5.8% versus 1.7%/yr for tolvaptan (P< 0.001, estimated ratio of geometric mean
0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined:−
2.1 versus− 0.71 ml/min per 1.73 m 2/yr (P= 0.01, LMM group difference 1.1 ml/min per 1.73 …
adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls
1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m 2) were similar. Control TKV
increased 5.8% versus 1.7%/yr for tolvaptan (P< 0.001, estimated ratio of geometric mean
0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined:−
2.1 versus− 0.71 ml/min per 1.73 m 2/yr (P= 0.01, LMM group difference 1.1 ml/min per 1.73 …